Company / Financials
Corcept Therapeutics Incorporated Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$761.4M
FY2025 · +12.8% YoY
Net Income
$99.7M
FY2025 · -29.4% YoY
Profit Margin
13.1%
FY2025 · net income / revenue
ROE
15.4%
FY2025 · return on equity
Total Assets
$836.7M
FY2025
Total Debt
-
FY2025
Equity
$647.8M
FY2025
ROA
11.9%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$761.4M+12.8% YoYNet Income HistoryProfit after all expenses and taxes$99.7M-29.4% YoYGross Profit HistoryRevenue minus cost of goods sold$63.6MCost of Revenue HistoryDirect costs of producing goods and services sold$13.0M+19.3% YoYOperating Income HistoryProfit from core business operations before interest and taxes$44.8M-67.3% YoYSG&A Expense HistorySelling, general, and administrative expenses$448.7M+60.1% YoYR&D Expense HistoryResearch and development spending$254.9M+3.2% YoYInterest Expense HistoryCost of borrowing and debt obligations$1.7MIncome Tax HistoryTotal income tax expense-$33.2M-263.6% YoYEPS (Basic) HistoryBasic earnings per share$1.02+7.4% YoY